secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001140361-26-017637
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B
--------------------------------------------------------------------------------

- Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.
- TRYNGOLZA net sales $27M; DAWNZERA $16M (+125% QoQ); royalties $58M, R&D revenue $138M incl. $95M milestones.
- 2026 guidance raised: total revenue $875-900M (from $800-825M); non-GAAP op. loss $425-475M (from $500-550M).
- Olezarsen sHTG sNDA accepted for Priority Review (PDUFA June 30); peak net sales guidance raised to >$3B.
- Zilganersen NDA for Alexander disease accepted Priority Review (PDUFA Sept 22); bepirovirsen NDA also accepted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/0001140361-26-017637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/ef20071749_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-017637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer